Health and Medicine Correspondent
Covers clinical evidence and the systems that deliver it. Weighs effect sizes against headlines and tracks which trial results ever reach the public record.
Registration was supposed to end selective publication. Two decades on, compliance with reporting requirements remains close to a coin flip, and enforcement is rare.
New antibiotics keep reaching approval and then bankrupting their developers. The problem is a business model that punishes exactly the drugs we most need held in reserve.
